82P - Plasma Proneurotensin as a Novel Biomarker for the Prediction of Incident Breast Cancer

Abstract

was related to incident diabetes (74 events; HR, 1.41; 95% CI, 1.12-1.77; P = .003), cardiovascular disease (224 events; HR, 1.33; 95% CI, 1.17-1.51; P < .001), total mortality (285 events; HR, 1.13; 95% CI, 1.01-1.27; P = .03), and cardiovascular mortality (75 events; HR, 1.50; 95% CI, 1.20-1.87; P < .001) whereas no such associations were seen in men. Adding P-NT on top of all breast cancer risk factors, significantly correctly reclassified women across categories of 10-year risk of breast cancer with a Net Reclassification Improvement of 20%. Of women who later developed breast cancer, 26% were moved to a higher category of risk whereas 21% of women who did not develop breast cancer were moved to a lower category of risk. Conclusion: Fasting proneurotensin was significantly associated with the development of breast cancer, diabetes, cardiovascular disease, and with total and cardiovascular mortality. It significantly improves stratification of future breast cancer risk which may be of clinical importance for radiological screening intensity. Disclosure: J. Struck: I am working with SphingoTec GmbH, a company which manufactures the Proneurotensin assay and holds patent rights on it A. Bergmann: Dr Bergmann is the president of Sphingotec GmbH which holds the patent rights for use of pro-neurotensin in prediction of diabetes, cardiovascular disease and breast cancer.All other authors have declared no conflicts of interest.